FDA pharmacologic class
CD20-directed Cytolytic Antibody
5 medicines are in FDA's class of cd20-directed cytolytic antibodies: rituximab (Rituxan), obinutuzumab (Gazyva), ocrelizumab (Ocrevus), ofatumumab (Kesimpta) and ublituximab (Briumvi); 2 combination products also contain one. 0 of the 7 are listed from generic labelers (FDA NDC Directory, October 8, 2026). The lowest pharmacy cost is kesimpta 20 mg/0.4 ml pen at $24,369.37 per mL (NADAC).
Which medicines are cd20-directed cytolytic antibody?
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Rituximab | Riabni, Ruxience, Rituxan | none listed | n/a | Yes | No current entry | 1 |
| Hyaluronidase and rituximab | Rituxan | none listed | n/a | Yes | No current entry | 0 |
| Hyaluronidase and ocrelizumab | Ocrevus | none listed | n/a | No | No current entry | 0 |
| Obinutuzumab | Gazyva | none listed | n/a | Yes | No current entry | 0 |
| Ocrelizumab | Ocrevus | none listed | n/a | No | No current entry | 0 |
| Ofatumumab | Kesimpta | none listed | $24,369.37 per mL 20 mg/0.4 mL pen | No | No current entry | 0 |
| Ublituximab | Briumvi | none listed | n/a | No | No current entry | 0 |
Source: FDA Established Pharmacologic Class (NDC Directory, openFDA); CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price